An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT02343744 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Pustular Psoriasis

Interventions

DRUG: Guselkumab

Sponsor

Janssen Pharmaceutical K.K.